The Rosuvastatin In TrAnsplant Recipients Study

Inclusion Criteria: * Renal transplant recipients with stable renal function (plasma creatinine \< 200 µmol/L) * Renal transplant recipients on an everolimus and fluvastatin based therapy for minimum 3 months prior to inclusion * \> 18 years of age * Male patient or female patient without childbearing potential (surgically sterilized or postmenopausal) or if female of childbearing potential; is not lactating, has a negative pregnancy test at screening and is willing to utilize an effective method of contraception throughout the study period and for 90 days following discontinuation of the study drugs * Signed informed consent Exclusion Criteria: * Patients experiencing an acute rejection episode within 2 weeks before or after inclusion, whether proven by biopsy or not * Patients with a known hypersensitivity to rosuvastatin * Change in enzyme inducing or inhibiting drugs within the last 2 weeks prior to and throughout the study \[e.g. barbiturates, rifampicin, ketoconazole, erythromycin, cimetidine and similar drugs\] * Pregnant or nursing mothers